首页 > 市场调查报告书 > 製药

癌症骨疾病

市场调查报告书

商品编码

1370268

多发性骨髓瘤药物市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: 2023年10月15日 | 出版商:

IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

抽象的

市场概况：

2022年，全球多发性骨髓瘤药物市场规模达到210亿美元。展望未来，IMARC集团预计到2028年市场规模将达到296亿美元，2023-2028年复合年增长率（CAGR）为6.3%。

多发性骨髓瘤或卡勒氏症是指一种主要影响浆细胞的血癌。一些最常见的多发性骨髓瘤药物类型包括化疗药物、皮质类固醇和免疫调节药物。这些药物有助于促进骨癒合，预防高血钙、骨折、脊髓压迫和贫血，同时最大限度地减少化疗的需要。化疗剂包括各种蒽环类抗生素和烷化剂，例如美法崙、阿霉素、长春新碱和脂质体阿霉素。标靶治疗药物包括蛋白酶体抑制剂，如硼替佐米，以及各种其他化合物，包括地塞米松、泼尼松和沙利度胺。

医疗保健领域的重大发展以及血液癌症盛行率的增加是推动市场成长的关键因素之一。多发性骨髓瘤通常是由特定的基因异常引起的，这种疾病的治疗涉及调节免疫系统的药物，并有助于提高化疗、放疗、干细胞移植和血小板输注的效率。此外，消费者对生物治疗药物益处的认识不断提高，生物治疗药物利用人体的免疫系统来识别和攻击骨髓瘤细胞，也推动了市场的成长。此外，各种技术进步，例如用于治疗多发性骨髓瘤的 microRNA 疗法和奈米药物的开发，正在成为另一个生长诱导因素。这些药物用于促进大分子药物输送到骨髓并催化抗肿瘤反应。其他因素，包括医疗保健支出的增加以及医学领域广泛的研发（R&D）活动，预计将进一步推动市场发展。

本报告回答的关键问题：

迄今为止，全球多发性骨髓瘤药物市场表现如何，未来几年将如何表现？
主要区域市场有哪些？
COVID-19 对全球多发性骨髓瘤药物市场有何影响？
基于该疗法的市场区隔是什么？
根据药物类型分類的市场是怎么样的？
基于最终用户的市场区隔是什么？
基于配销通路的市场区隔是什么？
产业价值链的各个阶段是什么？
该行业的关键驱动因素和挑战是什么？
全球多发性骨髓瘤药物市场的结构如何？谁是主要参与者？
产业竞争程度如何？

北美洲
- 美国
  - 市场走向
  - 市场预测
- 加拿大
  - 市场走向
  - 市场预测
亚太地区
- 中国
  - 市场走向
  - 市场预测
- 日本
  - 市场走向
  - 市场预测
- 印度
  - 市场走向
  - 市场预测
- 韩国
  - 市场走向
  - 市场预测
- 澳洲
  - 市场走向
  - 市场预测
- 印尼
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
欧洲
- 德国
  - 市场走向
  - 市场预测
- 法国
  - 市场走向
  - 市场预测
- 英国
  - 市场走向
  - 市场预测
- 义大利
  - 市场走向
  - 市场预测
- 西班牙
  - 市场走向
  - 市场预测
- 俄罗斯
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
拉丁美洲
- 巴西
  - 市场走向
  - 市场预测
- 墨西哥
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
中东和非洲
- 市场走向
- 按国家/地区分類的市场细分
- 市场预测

第 12 章：SWOT 分析

概述
优势
弱点
机会
威胁

第 13 章：价值链分析

第 14 章：波特五力分析

概述
买家的议价能力
供应商的议价能力
竞争程度
新进入者的威胁
替代品的威胁

第 15 章：价格指标

第16章：竞争格局

市场结构
关键参与者
关键参与者简介
- Amgen Inc.
- Bristol Myers Squibb
- Daiichi Sankyo Co.
- Sanofi-Aventis Groupe (Genzyme Corporation)
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
- PHARMA MAR, SA
- Takeda Pharmaceutical Company Limited.
- Teva Pharmaceutical Industries Ltd.

简介目录图表

Product Code: SR112023A2169

Abstract

Market Overview:

The global multiple myeloma drugs market size reached US$ 21.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 29.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.3% during 2023-2028.

Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.

Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple myeloma drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy, drug type, end-user and distribution channel.

Breakup by Therapy:

Targeted Therapy

Biologic Therapy

Chemotherapy

Others

Breakup by Drug Type:

Immunomodulatory Drugs

Proteasome Inhibitors

Histone Deacetylase Inhibitors

Monoclonal Antibody Drugs

Steroids

Others

Breakup by End-User:

Men

Women

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.

Key Questions Answered in This Report:

How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global multiple myeloma drugs market?
What is the breakup of the market based on the therapy?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the end-user?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global multiple myeloma drugs market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Pipeline Assesment/Clinical Trial Products/Clinical Developments

5.1 PegIntron (Pegylated interferon alfa-2b)
5.2 Pomalidomide
5.3 Tanespimycin (KOS-953)
5.4 MLN 9708
5.5 SRT-501- 012
5.6 BHQ880
5.7 Panobinostat
5.8 ZIO-101
5.9 VEGF-Trap(Aflibercept)
5.10 Denosumab
5.11 Perifosine
5.12 Actimid (CC-5013)
5.13 Romidepsin
5.14 Plitidepsin (Aplidin)
5.15 Temsirolimus (Torisel)
5.16 Sorafenib
5.17 Bevacizumab

6 Global Multiple Myeloma Drugs Market

6.1 Market Overview
6.2 Market Performance
6.3 Impact of COVID-19
6.4 Market Forecast

7 Market Breakup by Therapy

7.1 Targeted Therapy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Biologic Therapy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Chemotherapy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Drug Type

8.1 Immunomodulatory Drugs
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Proteasome Inhibitors
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Histone Deacetylase Inhibitors
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Monoclonal Antibody Drugs
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Steroids
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast

9 Market Breakup by End-User

9.1 Men
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Women
- 9.2.1 Market Trends
- 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Retail Pharmacies
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Online Pharmacies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
10.4 Others
- 10.4.1 Market Trends
- 10.4.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Asia Pacific
- 11.2.1 China
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 Japan
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 India
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Australia
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Europe
- 11.3.1 Germany
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 France
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 Italy
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Spain
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Russia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 Amgen Inc.
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
  - 16.3.1.4 SWOT Analysis
- 16.3.2 Bristol Myers Squibb
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
  - 16.3.2.4 SWOT Analysis
- 16.3.3 Daiichi Sankyo Co.
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 SWOT Analysis
- 16.3.5 Johnson & Johnson Services, Inc.
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 Financials
  - 16.3.5.4 SWOT Analysis
- 16.3.6 Merck & Co., Inc.
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
  - 16.3.6.3 Financials
  - 16.3.6.4 SWOT Analysis
- 16.3.7 Novartis International AG
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Pfizer Inc.
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 PHARMA MAR, S.A.
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
- 16.3.10 Takeda Pharmaceutical Company Limited.
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
  - 16.3.10.3 Financials
  - 16.3.10.4 SWOT Analysis
- 16.3.11 Teva Pharmaceutical Industries Ltd.
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio
  - 16.3.11.3 Financials
  - 16.3.11.4 SWOT Analysis

简介目录图表

List of Figures

Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2022
Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2022
Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2022
Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2022
Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2017 & 2022
Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2017 & 2022
Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2017 & 2022
Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2022
Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
Figure 92: Global: Multiple Myeloma Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2023-2028
Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 7: Global: Multiple Myeloma Drugs Market Structure
Table 8: Global: Multiple Myeloma Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219

License/价格

多发性骨髓瘤药物市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

抽象的

市场概况：

本报告回答的关键问题：

目录

第一章：前言

第 2 章：范围与方法

第 3 章：执行摘要

第 4 章：简介

第 5 章：管道评估/临床试验产品/临床开发

第 6 章：全球多发性骨髓瘤药物市场

第 7 章：透过疗法进行市场区隔

第 8 章：按药物类型分類的市场

第 9 章：最终用户的市场区隔

第 10 章：按配销通路分類的市场细分

第 11 章：按地区分類的市场细分

第 12 章：SWOT 分析

第 13 章：价值链分析

第 14 章：波特五力分析

第 15 章：价格指标

第16章：竞争格局

Abstract

Market Overview:

Key Market Segmentation:

Breakup by Therapy:

Breakup by Drug Type:

Breakup by End-User:

Breakup by Distribution Channel:

Breakup by Region:

Competitive Landscape:

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Pipeline Assesment/Clinical Trial Products/Clinical Developments

6 Global Multiple Myeloma Drugs Market

7 Market Breakup by Therapy

8 Market Breakup by Drug Type

9 Market Breakup by End-User

10 Market Breakup by Distribution Channel

11 Market Breakup by Region

12 SWOT Analysis

13 Value Chain Analysis

14 Porters Five Forces Analysis

15 Price Indicators

16 Competitive Landscape

List of Figures

List of Tables